Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line
Latest Information Update: 21 Feb 2020
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- Acronyms BEYOND TRIAL
- 17 Feb 2020 Planned End Date changed from 1 Dec 2021 to 30 Nov 2022.
- 17 Feb 2020 Planned primary completion date changed from 1 May 2019 to 30 Nov 2020.
- 21 Nov 2018 Planned End Date changed from 4 Sep 2021 to 1 Dec 2021.